跳至主要内容
临床试验/CTRI/2022/08/044878
CTRI/2022/08/044878已完成未知

Carvedilol to prevent decompensation in patients with compensated advanced chronic liver disease without high risk varices with liver stiffness more than 20kPa : An open label randomised controlled trial - CaLD-20 trial

I0 个研究点目标入组 269 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
已完成
发起方
入组人数
269

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1.Patients with compensated advance chronic liver disease(cACLD) of non-viral etiologies with a LSM >20 kPa without HRVs on Endoscopy.
  • 2.For HCV related ACLD, those with LSM >20KpA despite achieving sustained virological response at week-12 after treatment.
  • 3.All patients of cACLD with LRVs on EGD.

排除标准

  • 1)Cirrhosis with clinical decompensations
  • 2)cACLD with HRVs on EGD
  • 3)Patients with LSM <15 kPa with varices on EGD
  • 4)cACLD with isolated gastric varices
  • 5)HCV related cACLD on direct acting antivirals
  • 6)cACLD with HCC or portal venous thrombosis
  • 7)cACLD with large porto-systemic shunts ( >10mm)
  • 8)Alcoholic hepatitis
  • 9)Pregnancy and lactation
  • 10)Previous use of beta-blockers in last 3 months
  • 11)Contraindication for beta-blockers
  • 12)Unwilling to participate
  • 13)Non-cirrhotic portal hypertension

研究者

发起方
I

相似试验